Rejection Clinical Trials

2 recruiting

Rejection Trials at a Glance

69 actively recruiting trials for rejection are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Not Applicable with 15 trials, with the heaviest enrollment activity in Los Angeles, Nashville, and Chicago. Lead sponsors running rejection studies include Assistance Publique - Hôpitaux de Paris, Hopital Foch, and Hospices Civils de Lyon.

Browse rejection trials by phase

Treatments under study

About Rejection Clinical Trials

Looking for clinical trials for Rejection? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Rejection trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Rejection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 69 trials

Recruiting

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Graft vs Host DiseaseGraft-versus-leukemiaGraft Rejection
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00106925
Recruiting
Phase 4

Allograft Dysfunction in Heart Transplant

Heart Transplant Failure and Rejection
Paul Kim376 enrolled1 locationNCT03102125
Recruiting

Endothelial Glycocalyx Damage in Brain Death Organ Donors

Brain Damage Due to HypoxiaOrgan DonorsOrgan Transplant Failure or Rejection
University Hospital Hradec Kralove100 enrolled1 locationNCT05609123
Recruiting
Not Applicable

Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients

Lung Transplant Rejection
Mayo Clinic100 enrolled1 locationNCT06824402
Recruiting
Phase 2Phase 3

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Kidney Transplant Rejection
Sanofi526 enrolled10 locationsNCT07412470
Recruiting

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

Cardiac FailureGraft Rejection
Inova Health Care Services250 enrolled7 locationsNCT06939751
Recruiting
Phase 3

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Lung Transplant Rejection
Sanofi180 enrolled79 locationsNCT06082037
Recruiting
Phase 3

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

Kidney Transplant Failure and RejectionBK ViremiaKidney Transplant Infection
The University of Queensland280 enrolled12 locationsNCT05325008
Recruiting

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Cardiac FailureGraft Rejection
Inova Health Care Services150 enrolled7 locationsNCT06532890
Recruiting

Trifecta-Kidney cfDNA-MMDx Study

Kidney Transplant Rejection
University of Alberta300 enrolled31 locationsNCT04239703
Recruiting
Phase 2

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Antibody-mediated Rejection
argenx30 enrolled23 locationsNCT06503731
Recruiting

Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity

Antibody Mediated Rejection After Kidney Transplantation
Assistance Publique - Hôpitaux de Paris45 enrolled2 locationsNCT07134491
Recruiting
Phase 2

Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection

Lung Transplant Rejection
University of Virginia60 enrolled1 locationNCT07046910
Recruiting
Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Antibody-mediated Rejection
Biogen120 enrolled59 locationsNCT06685757
Recruiting

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

Kidney Transplant Rejection
Virginia Commonwealth University50 enrolled1 locationNCT07415876
Recruiting
Not Applicable

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

Kidney Transplant Rejection
Shahid Beheshti University of Medical Sciences50 enrolled1 locationNCT07006532
Recruiting

Prospective Study of White Blood Cells

InflammationAutoimmune DiseasesRejection; Transplant, Liver
Quell Therapeutics Limited10 enrolled1 locationNCT04838171
Recruiting
Phase 1

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

Antibody Mediated Rejection of Lung Transplant
Washington University School of Medicine30 enrolled2 locationsNCT06990711
Recruiting

Platelet Aggregation in the Diagnosis of Acute Graft Rejection

Kidney Transplant RejectionPlatelet Aggregation
University Hospital, Martin60 enrolled1 locationNCT07275541
Recruiting
Phase 1Phase 2

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

Kidney TransplantToleranceRenal Transplant Rejection
Jeffrey Veale, MD15 enrolled1 locationNCT03707262